Market Overview - A-shares showed mixed performance with the Shanghai Composite Index down 0.01%, Shenzhen Component Index up 0.19%, and ChiNext Index down 0.29% as of market close [1] - Total trading volume in Shanghai, Shenzhen, and Beijing reached 25,568 billion, an increase of 756 billion from the previous day [1] ETF Performance - The China-Korea Semiconductor ETF surged by 9.64%, leading the market, driven by the recovery in the semiconductor supply chain [2] - The National 2000 ETF rose by 5.04%, indicating a rebound in small-cap growth stocks [2] - The Electric Grid sector performed well, with the Electric Grid ETF up 3.23% and the Electric Grid Equipment ETFs rising by 3.22% and 2.91% respectively [2] Communication Sector - The communication sector also saw gains, with ETFs in this category rising between 2.73% and 2.78% [3] Declining Sectors - The pharmaceutical sector faced a broad retreat, with the Hang Seng Biotechnology ETF showing the largest decline at -3.89% [4] - Other related ETFs in the healthcare and biotechnology sectors also experienced significant drops, indicating a market shift from defensive sectors to technology growth [4] Trading Activity - The Short-term Bond ETF had a trading volume exceeding 66 billion, leading in activity among ETFs [5] - The top traded ETFs included the Short-term Bond ETF at 661.12 billion and the Silver Day Benefit ETF at 167.16 billion [5] Turnover Rates - Cross-border products showed high trading activity, with the Brazil ETF and China-Korea Semiconductor ETF having turnover rates of 171.99% and 125.76% respectively [6][7] - The National Debt ETF also maintained a strong turnover rate of 88.09%, indicating active trading in interest rate bonds and cross-border assets [7] New ETF Launch - A new Technology Growth ETF by Industrial Bank is set to launch on February 27, with a focus on hard technology and a multi-factor strategy targeting the top 50 securities in various tech sectors [8]

2024年9月24日以来，资本市场进入回暖上涨阶段，恒生生物科技指数累计涨幅达78.6%，跑赢港股通 创新药指数，展现出高弹性与高夏普比率的特征。 | | 恒生生物科技 | 恒生港股通创新药 | 港股通创新药 | 恒生医疗保健 | 港股通医疗主题 | | --- | --- | --- | --- | --- | --- | | 年化收益率(%) | 59. 42 | 57.50 | 59.07 | 51. 55 | 53. 41 | | 年化波动率(%) | 41.03 | 42.66 | 43. 50 | 39. 35 | 41.58 | | 最大回撤(%) | -27.55 | -27.35 | -27.08 | -28.51 | -30. 54 | | 夏普比率 | 1.45 | 1. 35 | 1.36 | 1.31 | 1.28 | | 累计收益(%) | 78. 64 | 75.97 | 78. 14 | 67.74 | 70. 29 | | 2025年以来收益(%) | 67. 50 | 66. 61 | 69.44 | 59.83 | 51. 12 | 数据来源：Wind，2025年以来数据 ...

国泰海通表示，AI技术正在推动制药领域的革新，英伟达与礼来合作建立AI+制药联合创新实验室，预 计未来五年投资最多10亿美元，以增强药物研发的核心生产力。TempusAI的业绩表明，AI在临床检测 与医疗数据商业化方面具有高度可复制性。当前，AI技术在制药行业的应用正迎来技术突破、资金活 跃和应用加速落地的共振阶段，推动行业向数据与算法驱动转型。 （文章来源：每日经济新闻） 恒生生物科技指数聚焦创新药"皇冠明珠"，具备龙头汇聚 × 稀缺期货活水 × 高弹性&高夏普三大优势。 投资者若希望便捷参与创新药核心龙头 ，可关注恒生生物科技ETF国泰（520933），实现一键布局。 ...